Welcome to Nymox Pharmaceutical Corporation


Nymox Pharmaceutical specializes in the research and development of novel drugs and diagnostic products for the aging population.  Nymox’s lead drug candidate is NX-1207, a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (BPH).  NX-1207 is currently in Phase 3 trials in the United States.  Nymox has other new drug products in development in the fields of cancer, infectious disease, neurodegenerative diseases, and other areas.